Advertisement
News
Advertisement

Alnylam joins Medtronic, CHDI to treat Huntington's disease

Wed, 11/03/2010 - 11:36am
Mass High Tech: The Journal of New England Technology

Cambridge biotech Alnylam Pharmaceuticals Inc. is collaborating with Minneapolis-based Medtronic Inc. and California non-profit CHDI Foundation Inc. to advance a drug-device combination treatment of Huntington’s disease, a neurodegenerative genetic disorder.

The treatment, ALN-HTT, is an RNAi therapeutic that targets the huntingtin gene associated with Huntington’s disease. Medtronic developed an implantable infusion system to deliver ALN-HTT. The virtual biotech firm CHDI is focused on the discovery and development of treatments for Huntington’s disease.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading